Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/db14-0776 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Lancet Diabetes Endocrinol
January 2022
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA; Imperial College London, London, UK.
Background: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients with HFrEF in addition to baseline treatment with specific doses and combinations of disease-modifying therapies.
Methods: We performed a post-hoc analysis of the EMPEROR-Reduced randomised, double-blind, parallel-group trial, which took place in 520 centres (hospitals and medical clinics) in 20 countries in Asia, Australia, Europe, North America, and South America.
Assessing the NOTCH2NLC GGC expansion in European patients with essential tremor.
Brain
December 2020
Department of Human Genetics, McGill University, Montréal, Quebec, Canada.
Interpretation of the Individual Effect Under Treatment Spillover.
Am J Epidemiol
August 2019
Department of Biostatistics, School of Public Health, Yale University, New Haven, Connecticut.
Some interventions are intended to benefit both individuals and the groups to which they belong. When a treatment given to one person exerts a causal effect on others, the treatment is said to exhibit spillover, dissemination, or interference. However, defining meaningful causal effects under spillover can be challenging.
View Article and Find Full Text PDFSpiegelman and Zhou Respond.
Am J Public Health
March 2019
Donna Spiegelman is with the Department of Biostatistics, Yale School of Public Health, New Haven, CT, and professor emerita in the Departments of Epidemiology, Biostatistics, Nutrition and Global Health, Harvard T. H. Chan School of Public Health, Boston, MA. Xin Zhou is with the Departments of Epidemiology and Biostatistics, Harvard T. H. Chan School of Public Health.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!